COCP - Cocrystal Pharma Inc

https://www.cocrystalpharma.com

Momentum: Bearish

Recent News

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference

GlobeNewswire • 1 week, 5 days ago • score: 0.29

BOTHELL, Wash., Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Cocrystal Pharma, Inc. ( Nasdaq: COCP ) ( "Cocrystal" or the "Company" ) announces that James Martin, CFO and co-CEO, will present a company overview at the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025 ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Cocrystal Pharma, Inc., a biotechnology company, is focused on the discovery and development of antiviral therapeutic treatments for serious and / or chronic viral diseases. The company is headquartered in Bothell, Washington.

52W High

$3.26

52W Low

$1.12

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

2.28

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.66

EV/Revenue (<3 favorable)

17.89

P/S (TTM) (<3 favorable)

92.45

P/B (<3 favorable)

2.84

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

36.05%

Institutions (25–75% balanced)

6.69%

Shares Outstanding

10,258,900

Float

6,639,800

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

510,000

Gross Profit (TTM)

-7,761,000

EPS (TTM)

-1.24

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-1.11%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.27

Momentum

Bearish momentum

Value

-0.0405

-0.0552

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025